PVLA
Palvella Therapeutics, IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.63B
P/E Ratio
—
EPS
$-4.17
Beta
—
52W High
$151.18
52W Low
$20.20
50-Day MA
$121.81
200-Day MA
$92.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc. is a biotechnology firm dedicated to advancing innovative therapies for rare genetic disorders resulting from specific gene mutations. The company’s lead investigational product targets pachyonychia congenita, addressing critical unmet medical needs in this specialized patient population. With a strong emphasis on gene therapy and a commitment to expanding its pipeline, Palvella is poised to significantly impact rare disease treatment. Its strategic focus on research and development underscores its potential to transform standard care and offers a promising investment opportunity for institutional investors.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -34.30% |
| Return on Assets | -16.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $16.23 |
| Price-to-Book | 7.04 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.34M |
| Float | $9.58M |
| % Insiders | 11.65% |
| % Institutions | 95.89% |
Historical Volatility
HV 10-Day
67.24%
HV 20-Day
77.87%
HV 30-Day
66.54%
HV 60-Day
68.13%
HV Rank
34.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($229.00 target)
15
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026